BriaCell’s Bria-OTS Achieves 11-Month Complete Resolution of Lung Metastasis in Advanced Breast Cancer Patient
Key Finding: Durable Response Maintained Without Treatment-Limiting Toxicities
In a significant update for metastatic breast cancer research, BriaCell Therapeutics announced that its investigational immunotherapy, Bria-OTS, delivered an 11-month sustained, complete resolution of lung metastasis in a patient participating in its Phase 1/2a study. Uniquely, the patient—who had hormone receptor-positive, HER2-negative metastatic breast cancer and multiple prior treatment failures—showed no treatment-limiting toxicities after 17 Bria-OTS cycles.
Patient Case: Consistent Efficacy Over Nearly a Year
The first patient dosed in the Bria-OTS study, a 78-year-old woman, achieved complete (100%) resolution in a lung metastasis within two months following four doses. This promising result was not a one-off: it was reconfirmed via imaging at 4, 6, and now 11 months. The patient completed 12 months on study and remains under follow-up, with no progression at other evaluable sites.
| Time Since Treatment | Lung Metastasis Outcome | Other Sites | Toxicity Observed |
|---|---|---|---|
| 2 months | 100% resolution | Stable disease | None |
| 4 months | Confirmed resolution | Stable disease | None |
| 6 months | Confirmed resolution | Stable disease | None |
| 11 months | Confirmed resolution | Stable disease | None |
Study Moves Into Combination Phase: Potential Implications for Future Treatment
Following the completion of dose escalation, the Bria-OTS trial is now progressing to Phase 2a, where it will evaluate Bria-OTS in combination with immune checkpoint inhibitors. The sustained clinical response seen in the first patient provides meaningful support for continuing the study and signals BriaCell’s intent to explore broader applications in advanced breast cancer populations.
Expert View: Confidence Grows in Bria-OTS Platform
BriaCell’s leadership and clinical investigators highlighted the relevance of these results, particularly for those with advanced, treatment-resistant cancer. “The sustained clinical response observed in this late-stage patient who had progressed through multiple prior treatments is remarkable,” noted Dr. Neal S. Chawla, Principal Investigator. Dr. William V. Williams, BriaCell’s CEO, added, "These findings reinforce our confidence in the therapeutic potential and safety of the Bria-OTS platform."
Takeaway: What Does This Mean for Patients—and Investors?
Though these early results are based on a single patient, the magnitude and durability of response—especially in someone with heavily pretreated disease—are noteworthy. If similar outcomes are reproduced in additional patients, Bria-OTS could offer hope for those with limited treatment options. With the trial advancing, observers will be watching closely as combination data are disclosed.
For more details on BriaCell’s clinical programs, visit briacell.com.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI